Brief: Sedana Q4 Operating Loss Widens To SEK 23.2 Mln
Feb 16 (Reuters) - Sedana Medical AB (publ) SEDANA.ST :
* NET SALES FOR QUARTER TOTALLED MSEK 35.8 (46.4),
EQUIVALENT TO A
DECREASE OF 23% COMPARED TO 2021
* Q4 OPERATING INCOME (EBIT) TOTALLED MSEK -23.2 (-18.7),
EQUIVALENT TO AN EBIT MARGIN OF -65% (-40%).
* PROPOSES THAT NO DIVIDEND BE PAID FOR 2022 FINANCIAL YEAR.
Source text for Eikon: ID:nWkr8Pzr8F
Further company coverage: SEDANA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Sedana Medical AB (publ)
See all newsSweden's Sedana Medical Q3 sales rise as growth returns
Brief: Sedana Medical Announces PDUFA Target Action Date
Brief: Sedana Medical Announces FDA Acceptance For Review Of Its New Drug Application In U.S.
Sweden's Sedana Medical Q2 sales flat, EBITDA loss narrows
Brief: Sedana Medical Q2 EBITDA Loss Narrows To SEK 1.9 Mln